[Indication and achievements of after-care examinations of urologic tumors. Chemotherapeutic report].
D000359:Aftercare; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008937:Mitomycins / Q000627:therapeutic use; D008926:Plicamycin / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy; D011344:Procarbazine / Q000627:therapeutic use; D014565:Urogenital Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008937:Mitomycins; D001761:Bleomycin; D003609:Dactinomycin; D011344:Procarbazine; D014747:Vinblastine; D003520:Cyclophosphamide; D008926:Plicamycin; D008558:Melphalan; D005472:Fluorouracil; D008727:Methotrexate
Indikation und Leistung der Nachsorgeuntersuchung bei urologischen Tumoren. Chemotherapeutisches Referat